KHK4083

DRUG4 trials

Sponsors

Kyowa Kirin, Inc., Kyowa Kirin Co., Ltd.

Conditions

Abdominal PainAtopic DermatitisAutoimmune DiseaseColitisColitis, UlcerativeColonic DiseasesDermatitis, AtopicDigestive System Diseases

Phase 1

A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative Colitis

CompletedNCT02985593

Kyowa Kirin Co., Ltd.Healthy Men and Subjects With Ulcerative Colitis

Start: 2016-12-31End: 2017-12-26Updated: 2023-08-30

A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis

CompletedNCT03096223

Kyowa Kirin Co., Ltd.Dermatitis, Atopic

Start: 2017-04-10End: 2018-02-07Updated: 2018-03-27

Phase 2

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

CompletedNCT02647866

Kyowa Kirin, Inc.Abdominal Pain, Autoimmune Disease, Colitis +7

Start: 2016-06-30End: 2018-10-31Updated: 2024-04-26

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

CompletedNCT03703102

Kyowa Kirin, Inc.Atopic Dermatitis

Start: 2018-10-22End: 2020-11-12Updated: 2024-04-26

Related Papers

Psychometric Evaluation of Worst Pruritus Numeric Rating Scale in Adults With Moderate-to-Severe Atopic Dermatitis.

2026-01-16

Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody

CPT Pharmacometrics & Systems Pharmacology2025-07-14

Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study

Dermatology and Therapy2024-11-123 citations

Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimab

Archives of Dermatological Research2024-11-065 citations

679 - Rocatinlimab significantly improves clinical responses in patients with moderate-to-severe atopic dermatitis by week 2 in a randomized double-blind placebo-controlled phase 2b study

British Journal of Dermatology2024-08-011 citations

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.

2022-12-09123 citations